Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter A Crooks

Showing results (271-280 of 319) with videos related to

Pageof 32
Sort By:
Molecules (Basel, Switzerland)|April 23, 2020
Oxone<sup>®</sup>-Mediated TEMPO-Oxidized Cellulose Nanomaterials form I and form IIJohn P Moore Ii, Soma Shekar Dachavaram, Shobanbabu Bommagani, et al.
The Journal of Surgical Research|October 24, 2007
Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancerReid C Vegeler, Michele T Yip-Schneider, Matthew Ralstin, et al.
Investigational New Drugs|October 12, 2012
The novel antiangiogenic VJ115 inhibits the NADH oxidase ENOX1 and cytoskeleton-remodeling proteinsAmudhan Venkateswaran, David B Friedman, Alexandra J Walsh, et al.
European Journal of Medicinal Chemistry|July 6, 2021
Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD)Narsimha R Penthala, Meenakshisundaram Balasubramaniam, Soma Shekar Dachavaram, et al.
Biochemical Pharmacology|March 30, 2010
Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine releaseAndrew M Smith, Marharyta Pivavarchyk, Thomas E Wooters, et al.
Journal of Pharmaceutical Sciences|February 19, 2010
Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigsStan L Banks, Raghotham R Pinninti, Harvinder S Gill, et al.
Drug and Alcohol Dependence|November 2, 2018
An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic α6β2* antagonist r-bPiDISarah E Maggio, Meredith A Saunders, Kimberly Nixon, et al.
British Journal of Pharmacology|January 15, 2011
bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuseThomas E Wooters, Andrew M Smith, Marharyta Pivavarchyk, et al.
Medchemcomm|August 11, 2015
Synthesis and evaluation of a series of resveratrol analogues as potent anti-cancer agents that target tubulinNikhil R Madadi, Hongliang Zong, Amit Ketkar, et al.
Biochemical Pharmacology|August 31, 2007
Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD)Linda P Dwoskin, B Matthew Joyce, Guangrong Zheng, et al.
Pageof 32

Showing results (271-280 of 319) with videos related to

Sort By:
Pageof 32
Molecules (Basel, Switzerland)|April 23, 2020
Oxone<sup>®</sup>-Mediated TEMPO-Oxidized Cellulose Nanomaterials form I and form IIJohn P Moore Ii, Soma Shekar Dachavaram, Shobanbabu Bommagani, et al.
The Journal of Surgical Research|October 24, 2007
Effect of celecoxib and novel agent LC-1 in a hamster model of lung cancerReid C Vegeler, Michele T Yip-Schneider, Matthew Ralstin, et al.
Investigational New Drugs|October 12, 2012
The novel antiangiogenic VJ115 inhibits the NADH oxidase ENOX1 and cytoskeleton-remodeling proteinsAmudhan Venkateswaran, David B Friedman, Alexandra J Walsh, et al.
European Journal of Medicinal Chemistry|July 6, 2021
Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD)Narsimha R Penthala, Meenakshisundaram Balasubramaniam, Soma Shekar Dachavaram, et al.
Biochemical Pharmacology|March 30, 2010
Repeated nicotine administration robustly increases bPiDDB inhibitory potency at alpha6beta2-containing nicotinic receptors mediating nicotine-evoked dopamine releaseAndrew M Smith, Marharyta Pivavarchyk, Thomas E Wooters, et al.
Journal of Pharmaceutical Sciences|February 19, 2010
Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigsStan L Banks, Raghotham R Pinninti, Harvinder S Gill, et al.
Drug and Alcohol Dependence|November 2, 2018
An improved model of ethanol and nicotine co-use in female P rats: Effects of naltrexone, varenicline, and the selective nicotinic α6β2* antagonist r-bPiDISarah E Maggio, Meredith A Saunders, Kimberly Nixon, et al.
British Journal of Pharmacology|January 15, 2011
bPiDI: a novel selective α6β2* nicotinic receptor antagonist and preclinical candidate treatment for nicotine abuseThomas E Wooters, Andrew M Smith, Marharyta Pivavarchyk, et al.
Medchemcomm|August 11, 2015
Synthesis and evaluation of a series of resveratrol analogues as potent anti-cancer agents that target tubulinNikhil R Madadi, Hongliang Zong, Amit Ketkar, et al.
Biochemical Pharmacology|August 31, 2007
Discovery of a novel nicotinic receptor antagonist for the treatment of nicotine addiction: 1-(3-Picolinium)-12-triethylammonium-dodecane dibromide (TMPD)Linda P Dwoskin, B Matthew Joyce, Guangrong Zheng, et al.
Pageof 32